Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017

Global Markets Direct’s, ‘Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017’, provides an overview of the Exocrine Pancreatic Insufficiency pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency

The report reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Exocrine Pancreatic Insufficiency therapeutics and enlists all their major and minor projects

The report assesses Exocrine Pancreatic Insufficiency therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Exocrine Pancreatic Insufficiency

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Anthera Pharmaceuticals Inc

Celleron Therapeutics Ltd

Cilian AG

Laboratoires Mayoly Spindler SAS

Nordmark Arzneimittel GmbH & Co KG

Anthera Pharmaceuticals Inc

Celleron Therapeutics Ltd

Cilian AG

Laboratoires Mayoly Spindler SAS

Nordmark Arzneimittel GmbH & Co KG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Exocrine Pancreatic Insufficiency – Overview

Exocrine Pancreatic Insufficiency – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Exocrine Pancreatic Insufficiency – Overview

Exocrine Pancreatic Insufficiency – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Exocrine Pancreatic Insufficiency – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Exocrine Pancreatic Insufficiency – Companies Involved in Therapeutics Development

Anthera Pharmaceuticals Inc

Celleron Therapeutics Ltd

Cilian AG

Laboratoires Mayoly Spindler SAS

Nordmark Arzneimittel GmbH & Co KG

Exocrine Pancreatic Insufficiency – Drug Profiles

burlulipase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cilase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CXD-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

liprotamase – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-1819 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Exocrine Pancreatic Insufficiency – Dormant Projects

Exocrine Pancreatic Insufficiency – Discontinued Products

Exocrine Pancreatic Insufficiency – Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura

Nov 09, 2017: Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura

Nov 02, 2017: Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference

Oct 20, 2017: AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier Submission

Sep 27, 2017: AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)

Sep 07, 2017: Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis

Aug 23, 2017: AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis

Aug 14, 2017: Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network

Jul 10, 2017: Anthera Pharmaceuticals Announces Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network

Jul 06, 2017: Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura

May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura

Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial

Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency

Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients

Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017

Number of Products under Development by Companies, H2 2017

Products under ...

List of Tables

Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Exocrine Pancreatic Insufficiency – Pipeline by Anthera Pharmaceuticals Inc, H2 2017

Exocrine Pancreatic Insufficiency – Pipeline by Celleron Therapeutics Ltd, H2 2017

Exocrine Pancreatic Insufficiency – Pipeline by Cilian AG, H2 2017

Exocrine Pancreatic Insufficiency – Pipeline by Laboratoires Mayoly Spindler SAS, H2 2017

Exocrine Pancreatic Insufficiency – Pipeline by Nordmark Arzneimittel GmbH & Co KG, H2 2017

Exocrine Pancreatic Insufficiency – Dormant Projects, H2 2017

Exocrine Pancreatic Insufficiency – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017

Number of Products under Development by Companies, H2 2017

Number of ...

List of Figures

Number of Products under Development for Exocrine Pancreatic Insufficiency, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports